|
|
 |
|
AMEVIVE® Reimbursement
AMEVIVE is an eligible benefit through most private insurance plans as per it's indication. Please choose the appropriate drug plan from the sidebar menu for specific information on AMEVIVE reimbursement.
Indication
AMEVIVE™ (alefacept) is indicated for treatment of patients with moderate to severe chronic plaque psoriasis who are candidates for phototherapy or systemic therapy.
AMEVIVE (alefacept) should not be administered to patients with known hypersensitivity to AMEVIVE or any of its components.
AMEVIVE (alefacept) induces dose-dependant reductions in circulating CD4+ and CD8+ T lymphocyte counts. AMEVIVE should not be administered to patients with a baseline total lymphocyte or CD4+ T cell count below normal. Beginning two weeks after the first dose, the CD4+ T lymphocyte counts should be monitored every two weeks during dosing and continuing throughout the course of the 12-week dosing regimen to guide subsequent dosing. If the CD4+ count falls below 250 cells/µL, subsequent doses of AMEVIVE should be withheld until the CD4+ T cell count increases to 250 cells/µL or more. AMEVIVE should be permanently discontinued in patients if CD4+ T lymphocyte counts remain below 250 cells/µL for one month. Prior to initiating another course of therapy, it is recommended that patients have total lymphocyte and CD4+ T cell counts within the normal range. The most common observed adverse events in the fi rst course of placebo-controlled clinical trials were: headache (17%, placebo 18%), accidental injury (15%, placebo 13%), pharyngitis (15%, placebo 13%), infection (11%,placebo 11%), pruritus (11%, placebo 8%) rhinitis (11%, placebo 10%). Chills was the only event seen at an incidence of 5% or greater in Amevive patients (6%) versus placebo-treated patients (1%). AMEVIVE has the potential to increase the risk of infection and may reactivate latent, chronic infections. AMEVIVE should be used with caution in patients with a history of such infections and should not be administered in patients with a clinically important infection. Patients who develop a new clinically significant infection while undergoing treatment with AMEVIVE should be clinically monitored closely. If a patient develops a severe infection, dosing should be discontinued until the infection is completely resolved. AMEVIVE should be discontinued in patients who develop clinical signs of liver injury. Caution should be exercised when considering the use of AMEVIVE in patients at high risk for malignancy. If a patient develops a malignancy, AMEVIVE should be discontinued.
Please consult the AMEVIVE Product Monograph for complete prescribing information.
Resources for Healthcare Professionals and Your Patients
AMEVIVE Care Program™ 1-877-263-8483 (1-877-AMEVIVE)
The AMEVIVE Care Program™ provides a 24-hr toll-free hotline, help in finding reimbursement, injection training and other materials necessary to start therapy.
AMEVIVE Care Program™ Patient Support Booklet
For patient-oriented information on living with psoriasis, AMEVIVE therapy, the AMEVIVE Care Program™ and frequently asked questions.
AMEVIVE Care Program™ Enrolment and Prescription Form
PsoriasisSupport.ca
® AMEVIVE is a registered trademark of Astellas US LLC.
|
|
|
|
